Read this company snapshot
Daily valuation snapshot
Taysha Gene Therapies, Inc. Common Stock: source evidence dated 2026-10-09.
- Daily close (USD)
- $4.49
- Market capitalization (USD)
- $1,462,992,617.05
- Price / earnings (TTM)
- Not reported
- Price / book
- 3.78
The source values and product destination above identify the example to inspect.
What business is this, and what does its dated valuation mean?
Check the market day first. P/E uses trailing earnings; book value and market capitalization answer different questions.
Daily valuation dataset and column definitionsOpen the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TSHA in the app
Open the company research view or ask Aurora to reconcile reporting periods, earnings, debt and the figures behind the valuation.
Research TSHA in the appKeep reporting dates and units beside the answer, and inspect its original citations.
Company overview
Taysha Gene Therapies, Inc., a clinical-stage biotechnology company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis. The company has research, collaboration, and license agreement with The University of Texas Southwestern Medical Center. Taysha Gene Therapies, Inc. was incorporated in 2019 and is headquartered in Dallas, Texas.
Daily valuation snapshot
See the complete daily valuation snapshot
These values come from the daily market snapshot dated 2026-10-09. TTM means trailing twelve months. Use the market date when comparing TSHA with another company.
Scroll sideways to compare all columns. Select a heading to sort.
| Daily close (USD) | $4.49 |
| Market capitalization (USD) | $1,462,992,617.05 |
| Price / earnings (TTM) | Not reported |
| Price / book | 3.78 |
No matching rows. Clear the filter to see all records.
Read TSHA's valuation metrics
Company size
Taysha Gene Therapies, Inc. Common Stock's recorded market capitalization is $1,462,992,617.05. It measures the market value of the company's equity, rather than its revenue or cash balance.
Price relative to earnings
P/E compares share price with trailing annual earnings per share. For a company with losses, inspect the earnings figures directly rather than treating a negative multiple as a cheap valuation.
Price relative to book equity
TSHA's recorded price-to-book ratio is 3.78. That compares its market equity value with recorded book equity. Examine its business and balance sheet to understand why those values differ.
Research Taysha Gene Therapies, Inc. Common Stock with Aurora
Use the snapshot above to ask a specific question about TSHA. Ask for the report period and the figures behind the explanation, then compare the answer with the company's business description.
Continue the research
Follow TSHA's ownership disclosures to see who filed a transaction or position and when it became public. To turn a research idea into a strategy, define an entry rule and test its dated observations.